Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Comparative Analysis Of Modified Vs. Classical Nuss Technique In The Surgical Correction Of Pectus Excavatum "

NCT07312448 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-12-02
Last updated
2025-12-31

Condition(s) studied

Pectus Excavatum

Study summary

Although the NUSS technique has become the standard minimally invasive procedure for correcting this deformity, there is a lack of comparative data between the classic and modified NUSS techniques. This research aims to fill this gap by comparing these two methods in terms of various outcomes, such as operative time, postoperative pain control, length of stay in the intensive care unit, and overall cosmetic results.

This study addresses the need to optimize surgical techniques to improve patient outcomes. By evaluating these two approaches, the research seeks to provide insights that could lead to better management strategies for patients with pectus excavatum, potentially influencing future clinical practices.

Eligibility

Sex
ALL
Min age
11 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 11 to 18 years. * Patients who underwent surgery between 2010 and 2024 using either the classic or modified Nuss technique. - Patient with a Haller index of 2.25 or higher. Exclusion Criteria: * Patients with a Haller score below 2.25. * Patients who have undergone surgery using alternative techniques such as Ravitch or modified Ravitch. * Patients under 11 years of age or over 19 years of age.

Primary outcome measure(s)

  • Operating time (in minutes) — Operating time (in minutes)
    Comparaison Of Modified Vs. Classical Nuss Technique In The Surgical Correction Of Pectus Excavatum in terms of operating time criterion (in minutes)

Trial sites (1)

FacilityCityRegionStatus
Service de Chirurgie Pédiatrique - Réanimation - CHU de Strasbourg - France Strasbourg France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07312448 on ClinicalTrials.gov ↗ ← All trials in France